NGL Fine-Chem Limited

NSE NGLFINE.NS

NGL Fine-Chem Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -129.63 K

NGL Fine-Chem Limited Net Cash Used Provided By Financing Activities is USD -129.63 K for the year ending March 31, 2024, a 1.46% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

NGL Fine-Chem Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD -131.55 K, a 7.62% change year over year.
NGL Fine-Chem Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -142.39 K, a 3.56% change year over year.
NGL Fine-Chem Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD -147.65 K, a 14.63% change year over year.
NGL Fine-Chem Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -172.96 K, a -290.21% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NSE: NGLFINE.NS

NGL Fine-Chem Limited

CEO	Mr. Rahul Jayant Nachane
IPO Date	July 8, 2022
Location	India
Headquarters	301, E Square
Employees	682
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Key trends

Past 5 years